Drugs / SOFITUZUMAB VEDOTIN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01335958 | Apr 2011 → Feb 2014 | exocrine pancreatic carcinoma, ovarian carcinoma | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOFITUZUMAB VEDOTIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545372 ↗ |
| Known as | Anti-MUC16 ADC | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545372 ↗ |
| Known as | DMUC5754A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01335958 ↗ |
| Known as | RG-7458 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545372 ↗ |
| Known as | Sofituzumab vedotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545372 ↗ |
| Known as | Sofituzumab vedotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545372 ↗ |
| Route | Intravenous | “administered as a single agent by intravenous (IV) infusion” NCT01335958 ↗ |
| Target | MUC16 | “Mucin-16 binding agent” CHEMBL3545372 ↗ |